egfr单抗联合奥沙利铂或伊立替康治疗晚期结直肠癌疗效与不良反应meta的分析

《egfr单抗联合奥沙利铂或伊立替康治疗晚期结直肠癌疗效与不良反应meta的分析》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、原创性声明1111111IIIIIIIIllUfY2182035本人郑重声明：所呈交的学位论文，是本人在导师的指导下，独立进行研究所取得的成果。除文中已经注明引用的内容外，本论文不包含任何其他个人或集体已经发表或撰写过的科研成果。对本文的研究作出重要贡献的个人和集体，均已在文中以明确方式标明。本声明的法律责任由本人承担。论文作者签名：兰啦日期：劢f2．岁．fD关于学位论文使用授权的声明本人完全了解山东大学有关保留、使用学位论文的规定，同意学校保留或向国家有关部门或机构送交论文的复印件和电子版，允许论文被查阅和借阅；

2、本人授权山东大学可以将本学位论文的全部或部分内容编入有关数据库进行检索，可以采用影印、缩印或其他复制手段保存论文和汇编本学位论文。(保密论文在解密后应遵守此规定)论文作者签名：哔导师签名：日期：丝!兰!圭』呈山东大学硕士学位论文目录中文摘要⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯3英文摘要⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯5符号说明⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯8前言⋯⋯⋯⋯⋯··⋯⋯⋯⋯⋯··⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯一⋯⋯⋯⋯⋯⋯9翮看⋯

3、⋯⋯⋯⋯“⋯⋯⋯⋯⋯一⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯”⋯⋯⋯⋯⋯⋯V材料与方法⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯1l结果⋯⋯·⋯⋯··⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·⋯··⋯”⋯⋯⋯⋯·16讨论⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯···⋯⋯⋯⋯⋯⋯22结论⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯··⋯⋯⋯⋯·26附表和附图⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯27参考文献⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯35综j苤⋯⋯⋯⋯⋯⋯⋯⋯

4、⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯···⋯⋯⋯⋯⋯40致谢⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯57山东大学硕士学位论文CATALOGUEChineseAbstract······························-···············································3EnglishAbstract··································································-···

5、········5SymbolDescription···········································································8Introduction····················································································9MaterialSandMethods··········································

6、···························11Results⋯⋯⋯⋯·····⋯·⋯⋯·⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯··16Discussion⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·⋯⋯⋯⋯⋯··⋯⋯⋯⋯⋯一⋯·⋯⋯⋯⋯22Conclusion⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·⋯⋯⋯⋯⋯⋯⋯··26FiguresandGraphs⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·⋯⋯⋯⋯⋯⋯··27References··············································

7、······························-·······35Review·······································-··················································40Acknowledgment⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯⋯·⋯···⋯⋯⋯⋯⋯··572山东大学硕士学位论文EGFR单抗联合奥沙利铂或伊立替康治疗晚期结直肠癌的疗效与不良反应的meta分析专业：肿瘤学硕士研究生：付帅导师：王秀问中文摘要研

8、究目的随着EGFR单抗在治疗晚期结直肠癌中所展示出的突出表现，对于EGFR单抗联合不同化疗方案应用所表现出的不同疗效与安全性引起了研究者的广泛关注，本文意在探讨对比以表皮生长因子受体(EGFR)为靶点的单克隆抗体联合奥沙利铂或伊立替康为基础的化疗方案的疗效与安全性的不同。材料与方法本文通过检索电子数据库Pubmed、EMBASE、TheCochraneLib